Turning Pennies into dollars: (OTCBB: PBME); (PINKSHEETS: VDTI); (OTCBB: CPTC).
Are you a public company looking for exposure?
Contact RealPennies.com - 1.800.940.6559
For more info: http://pbme.realpennies.com
Pacific Biometrics, Inc. (OTCBB: PBME) closed at $0.50 Friday, trading 42,000 shares.
Company News- April 7, 2008: Pacific Biometrics, Inc. Awarded Additional Research Contracts as Part of Global First-in-Class Arthritis Drug Program
Pacific Biometrics, Inc. (OTCBB: PBME) announced earlier today it has been awarded two contracts worth a combined $1.6 million with a top multinational pharmaceutical company (the "Sponsor"). These contracts are part of a series of four contracts, two of which were previously announced, related to clinical trials that form part of a global development program for an innovative biological treatment for rheumatoid arthritis (RA), and will provide essential laboratory data for a pivotal Phase III program.
Pacific Biometrics is specifically contracted to provide testing for an extensive panel of inflammatory, metabolic, cardiovascular, and musculoskeletal biomarkers to support the Sponsor's phase III clinical development program. The Sponsor ultimately hopes to submit a new drug application (NDA) filing with the FDA and equivalent filings with regulatory agencies in other jurisdictions. Testing for the newly awarded contracts is expected to begin at the end of the 2nd quarter of calendar 2008 and continue through the 4th quarter of calendar 2011.
"We are extremely pleased to have signed additional contracts for this pivotal, international phase III arthritis program, which is exciting on multiple fronts," said Ron Helm, Chief Executive Officer of Pacific Biometrics. "First of all, these studies will further strengthen our relationship with this Sponsor, who accounts for an important and growing percentage of our more diversified customer base. Second, our selection for this project is validation for our worldwide, best-in-class testing of biomarkers as they relate to the diagnosis and treatment of arthritis -- a growing area of expertise for the Company. Third, the drug in question is a highly innovative, first-in-class biologic agent for RA that may have applicability to a broader range of inflammatory diseases. Finally, assuming the scope of the studies remains unchanged, the contracts should have a meaningful impact on our fiscal 2009, 2010 and 2011 financial results."
About Pacific Biometrics, Inc. (PBI)
Established in 1989, PBI provides specialized central laboratory and contract research services to support pharmaceutical and diagnostic manufacturers conducting human clinical trial research. The company provides expert services in the areas of cardiovascular disease, diabetes, osteoporosis, arthritis, and nutrition. The PBI laboratory is accredited by the College of American Pathologists, and through its non-profit affiliate Pacific Biometrics Research Foundation, is one of only three U.S.-based members of the Centers for Disease Control (CDC) Cholesterol Reference Method Laboratory Network. PBI's clients include many of the world's largest pharmaceutical, biotech, and diagnostic companies.
Pacific Biomarkers, Inc., incorporated February 1, 2008 as a wholly owned subsidiary of Pacific Biometrics, Inc., focuses specifically on the emerging field of biomarker assay development and testing. Services include validating and performing ligand-binding assays for novel clinical biomarkers, immunogenicity testing, and multiplex testing.
For more information about Pacific Biometrics, visit the company's web site at www.pacbio.com.
For more info: http://vdti.realpennies.com
VitalCare Diabetes Treatment Centers, Inc. (PINKSHEETS: VDTI) closed at $0.55 Friday, trading 956 shares.
Company News- April 7, 2008: VitalCare Adds Tristan V. Voth-Stonger, MD as Executive VP & CMO
VitalCare Diabetes Treatment Centers, Inc. (PINKSHEETS: VDTI), a Nevada corporation, earlier today announced that Tristan V. Voth-Stonger, MD has accepted a position as Executive Vice President and Chief Medical Officer with VitalCare. Dr. Voth-Stonger is a Board Certified Plastic and Reconstructive Surgeon who specializes in reconstructive surgery and difficult wound care. Dr. Voth-Stonger graduated from medical school at Indiana University. Thereafter he went to Zurich, Switzerland to complete his fellowship in Orthopedic and hand surgery with a leading hand surgeon, after which he moved to Portland, Oregon (1973 - 1976) to complete his general surgery training as a prerequisite for his plastic and reconstructive surgical residency (1976 - 1978) at Albany Medical Center in Albany, NY. From (1978 - 1980) he completed fellowship training with several world class plastic and reconstructive surgeons, intermixed with missionary medical work in South and Central America. He furthered that opportunity as a visiting professor to Sri Lanka under an appointment from the University of California at Irvine. He has been in private practice since 1980. Dr. Voth-Stonger, a Lt. Colonel USAF from (1987 - 1994), served as a Flight Surgeon and Critical Medical Specialist and is a veteran of Desert Storm Operations. Mr. Jimmy A. McDougald, CEO and Chairman of VitalCare, stated, "We are pleased to have such a distinguished Physician on our Corporate Management Team. Dr. Voth-Stonger's extensive medical training and expertise combined with his knowledge of investment banking and business administration will benefit the Company at many levels." Dr. Tristan Voth-Stonger said, "I am excited to be part of VitalCare's answer to the treatment of Type 1 and Type 2 diabetes, using the Intracellular Activation Therapy (iCAT) protocol and FDA approved micro-dosing intravenous insulin pump. I am grateful for this opportunity to help VitalCare introduce iCAT so that it becomes available to all diabetic sufferers throughout North America."
About VitalCare Diabetes Treatment Centers, Inc.
VitalCare Diabetes Treatment Centers, Inc. is a company specializing in providing Administrative, Marketing, Business Development, Strategic Planning, Clinical Oversight and Clinical Management Services to the Diabetes Healthcare Sector, with an emphasis in bringing "Cutting Edge" medical devices and healthcare services direct to consumers, focusing on an emerging FDA approved, US and European Patented technology and treatment intervention for treating Type 1 and Type 2 Diabetes known as "Intracellular Activation Therapy (iCAT)."
For more info: http://cptc.realpennies.com
Composite Technology Corporation (OTCBB: CPTC) closed at $1.04 Friday, trading 2,117,271 shares.
Company News- April 7, 2008: Composite Technology Announces Certification for Its Flagship 60Hz DeWind D8.2 Wind Turbine
Composite Technology Corporation (CTC) (OTCBB: CPTC) announced earlier today that its DeWind subsidiary received certification of the 60 hertz version of their 2 Megawatt D8.2 wind turbine from DEWI-Offshore and Certification Centre GmbH (DEWI-OCC), according to International Electrotechnical Commission (IEC) requirements.
The Statement of Compliance for the Design Assessment of the 2 MW 60 Hz D8.2 with an 80 m rotor diameter and 80 m hub height tower was conducted for IEC Type IIA conditions and in conformance with IEC 61400-1 guidelines. This is a rigorous third party independent verification that confirms that the turbine components can be expect to achieve a 20 year design life under operating conditions that are equal to or more demanding than the majority of wind sites in the Americas.
"This is yet another important milestone in our certification campaign for the DeWind D8.2 family of turbines and provides assurance that the design of our 60 Hz version complies with the internationally recognized high standard for the North American, Central American and Brazilian markets," stated Benton Wilcoxon, Chairman and CEO of CTC.
About CTC
Composite Technology Corporation, based in Irvine, California, USA, develops, manufactures and sells innovative high performance electrical transmission and renewable energy generation products through its subsidiaries. For more information, please visit www.compositetechcorp.com.
Read our full disclaimer at: http://www.realpennies.com/start.html
Investors are advised that this analysis is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. This report does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this information. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Past performance is no guarantee of future results. Please consult a broker before purchasing or selling any securities mentioned on RealPennies. For more movers: http://www.realpennies.com/wrapup.html
Any opinions expressed herein are statements of our judgment as of the date of publication and are subject to change without notice.
Sitemap: http://www.realpennies.com/sitemap.html
Sponsored by: http://www.isthemarketopen.com
RealPennies .
Telephone: 1-800-940-6559
Matt /at/ realpennies.com
No comments:
Post a Comment